• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aligos Therapeutics Inc. (Amendment)

    2/14/24 4:00:27 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALGS alert in real time by email
    SC 13G/A 1 z110241sc13ga2.htm AMENDMENT NO. 2

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Aligos Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

     

    01626L105

    (CUSIP Number)

     

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

    Page 1 of 8
     

     

    CUSIP No. 01626L105 

     

    13G/A Page 2 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (
    b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,189,847

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    2,189,847

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,189,847

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    3.0% 

    12

    type of reporting person

     

    pN 

     

    Page 2 of 8
     

     

    CUSIP No. 01626L105 

     

    13G/A Page 3 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (
    b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,189,847

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    2,189,847

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,189,847

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    3.0% 

    12

    type of reporting person

     

    OO 

     

    Page 3 of 8
     

     

    CUSIP No. 01626L105 

     

    13G/A Page 4 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (
    b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    UNITED STATES

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,189,847

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    2,189,847

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,189,847

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    3.0%

    12

    type of reporting person

     

    IN 

     

    Page 4 of 8
     

     

    Item 1(a).Name of Issuer:

     

    Aligos Therapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    One Corporate Drive, 2nd Floor, South San Francisco, CA 94080

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 01626L105

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 2,189,847 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 2,189,847 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 2,189,847 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

    Page 5 of 8
     

     

    The percentages used herein are based on 71,839,510 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer’s Prospectus pursuant to Rule 424(b)(3) that was filed with the Securities and Exchange Commission on November 28, 2023.

     

    (b)Percent of Class:

     

    Tang Capital Partners 3.0%
    Tang Capital Management 3.0%
    Kevin Tang 3.0%

     

    (c)Number of shares as to which such person has:

     

    (i)       sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares
       

    (ii)      shared power to vote or to direct the vote:

     

    Tang Capital Partners 2,189,847 shares
    Tang Capital Management 2,189,847 shares
    Kevin Tang 2,189,847 shares
       

    (iii)      sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares
       

    (iv)     shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 2,189,847 shares
    Tang Capital Management 2,189,847 shares
    Kevin Tang 2,189,847 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Page 6 of 8
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 7 of 8
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8

     

     

     

     

    Get the next $ALGS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGS

    DatePrice TargetRatingAnalyst
    8/18/2025$50.00Buy
    H.C. Wainwright
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    3/11/2022$47.00 → $15.00Overweight
    Piper Sandler
    3/11/2022$10.00 → $11.00Outperform
    SVB Leerink
    2/16/2022$15.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $ALGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company's stock (the "Inducement Grant") to newly hired employees on January 29, 2026 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducem

    1/30/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

    SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection. "2026 is an important year for Aligos as we continue to make progress with the Phase 2 B-SUPREME study with 144 subjects currently enrolled across the world," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO. "We look forward to our interim analyses, which will contain directional

    1/21/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (("Aligos", NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company's global commercial capabilities and serve as a member of Aligos' Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. "As we continue to progress the Phase 2 B-

    1/13/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

    SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    2/11/26 4:32:25 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Aligos Therapeutics Inc.

    8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)

    2/4/26 4:05:42 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

    SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/25 4:15:45 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Blatt Lawrence

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 5:14:30 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Symons Julian A.

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 5:14:05 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Calhoun Lesley Ann

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    7/18/25 4:41:45 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aligos Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00

    8/19/24 6:51:07 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously

    1/6/23 9:05:04 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Financials

    Live finance-specific insights

    View All

    Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

    ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig

    9/19/24 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th

    9/18/24 5:00:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

    CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient

    3/10/22 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (("Aligos", NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company's global commercial capabilities and serve as a member of Aligos' Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. "As we continue to progress the Phase 2 B-

    1/13/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. "I am thrilled to welcome Ramón to the leadership team at Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón's extensive regulatory expertise will be a critical component as we th

    8/20/25 8:30:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

    SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. "I am pleased to welcome Kieron to Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "With decades of experience, Kieron's extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters."

    6/18/25 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:57:50 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:19:11 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 5:03:16 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care